Tiofarma Admits Involvement On UK Fludrocortisone
UK’s CMA Announces Agreement To Pay Up To £186,000
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.
